Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Praxis Precision Medicines ( (PRAX) ) has shared an update.
Praxis Precision Medicines, Inc. announced the termination of its 2024 Sales Agreement with Jefferies LLC on September 2, 2025, which previously allowed the company to sell shares of its common stock up to $250 million. This decision halts further sales under the 2024 ATM Program after raising approximately $86.2 million. Subsequently, on September 5, 2025, Praxis entered into a new sales agreement with TD Securities (USA) LLC to offer shares worth up to $250 million through an ‘at the market’ equity offering program, indicating a strategic shift in its capital-raising approach.
The most recent analyst rating on (PRAX) stock is a Buy with a $117.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Spark’s Take on PRAX Stock
According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.
Praxis Precision Medicines faces significant financial challenges, with ongoing net losses and negative cash flows being the most critical factors affecting its stock score. Despite these financial difficulties, the company has shown promising clinical developments and received positive regulatory feedback, which provides some optimism for future growth. Technical indicators and valuation metrics are currently unfavorable, further weighing down the overall score.
To see Spark’s full report on PRAX stock, click here.
More about Praxis Precision Medicines
Praxis Precision Medicines, Inc. operates within the biotechnology industry, focusing on developing treatments for central nervous system disorders. The company primarily engages in the research and development of therapies aimed at addressing neurological and psychiatric conditions, with a market focus on innovative precision medicines.
Average Trading Volume: 410,692
Technical Sentiment Signal: Sell
Current Market Cap: $970M
For detailed information about PRAX stock, go to TipRanks’ Stock Analysis page.